vs
百利高（PRGO）与Rivian Automotive, Inc.（RIVN）财务数据对比。点击上方公司名可切换其他公司
Rivian Automotive, Inc.的季度营收约是百利高的1.2倍（$1.3B vs $1.1B），Rivian Automotive, Inc.净利率更高（-63.1% vs -127.8%，领先64.7%），百利高同比增速更快（-2.5% vs -25.8%），百利高自由现金流更多（$148.6M vs $-1.1B），过去两年Rivian Automotive, Inc.的营收复合增速更高（3.3% vs 1.3%）
百利高（Perrigo）是一家注册于爱尔兰的非处方仿制药生产商，主打自有品牌OTC药品业务。公司70%的净销售额来自美国医疗市场，为优化税务布局将法定总部设在爱尔兰，该地区销售额仅占总营收的0.6%，2013年曾完成美国历史上第六大企业税收倒置交易。
Rivian Automotive是2009年成立的美国电动汽车制造商及汽车科技企业，主打基于自研滑板平台打造的电动SUV、皮卡及EDV电动配送货车，旗下R1T皮卡于2021年末正式开启交付，还计划于2023年底前在美国和加拿大布局专属充电网络，其平台可适配新车型也可对外授权使用。
PRGO vs RIVN — 直观对比
营收规模更大
RIVN
是对方的1.2倍
$1.1B
营收增速更快
PRGO
高出23.3%
-25.8%
净利率更高
RIVN
高出64.7%
-127.8%
自由现金流更多
PRGO
多$1.3B
$-1.1B
两年增速更快
RIVN
近两年复合增速
1.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $1.3B |
| 净利润 | $-1.4B | $-811.0M |
| 毛利率 | 32.6% | 9.3% |
| 营业利润率 | -116.0% | -64.8% |
| 净利率 | -127.8% | -63.1% |
| 营收同比 | -2.5% | -25.8% |
| 净利润同比 | -3093.9% | -9.0% |
| 每股收益（稀释后） | $-10.23 | $-0.66 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PRGORIVN
| Q4 25 | $1.1B | $1.3B | ||
| Q3 25 | $1.0B | $1.6B | ||
| Q2 25 | $1.1B | $1.3B | ||
| Q1 25 | $1.0B | $1.2B | ||
| Q4 24 | $1.1B | $1.7B | ||
| Q3 24 | $1.1B | $874.0M | ||
| Q2 24 | $1.1B | $1.2B | ||
| Q1 24 | $1.1B | $1.2B |
净利润PRGORIVN
| Q4 25 | $-1.4B | $-811.0M | ||
| Q3 25 | $7.5M | $-1.2B | ||
| Q2 25 | $-8.4M | $-1.1B | ||
| Q1 25 | $-6.4M | $-545.0M | ||
| Q4 24 | $-44.4M | $-744.0M | ||
| Q3 24 | $-21.0M | $-1.1B | ||
| Q2 24 | $-108.4M | $-1.5B | ||
| Q1 24 | $2.0M | $-1.4B |
毛利率PRGORIVN
| Q4 25 | 32.6% | 9.3% | ||
| Q3 25 | 36.1% | 1.5% | ||
| Q2 25 | 34.4% | -15.8% | ||
| Q1 25 | 37.6% | 16.6% | ||
| Q4 24 | 33.9% | 9.8% | ||
| Q3 24 | 37.2% | -44.9% | ||
| Q2 24 | 37.0% | -38.9% | ||
| Q1 24 | 33.1% | -43.8% |
营业利润率PRGORIVN
| Q4 25 | -116.0% | -64.8% | ||
| Q3 25 | 7.0% | -63.1% | ||
| Q2 25 | 4.3% | -85.5% | ||
| Q1 25 | 4.5% | -52.8% | ||
| Q4 24 | 10.0% | -38.1% | ||
| Q3 24 | 7.4% | -133.8% | ||
| Q2 24 | -2.5% | -118.7% | ||
| Q1 24 | -5.1% | -123.3% |
净利率PRGORIVN
| Q4 25 | -127.8% | -63.1% | ||
| Q3 25 | 0.7% | -75.3% | ||
| Q2 25 | -0.8% | -85.7% | ||
| Q1 25 | -0.6% | -44.0% | ||
| Q4 24 | -3.9% | -42.9% | ||
| Q3 24 | -1.9% | -125.9% | ||
| Q2 24 | -10.2% | -125.8% | ||
| Q1 24 | 0.2% | -120.1% |
每股收益（稀释后）PRGORIVN
| Q4 25 | $-10.23 | $-0.66 | ||
| Q3 25 | $0.05 | $-0.96 | ||
| Q2 25 | $-0.06 | $-0.97 | ||
| Q1 25 | $-0.05 | $-0.48 | ||
| Q4 24 | $-0.32 | $-0.67 | ||
| Q3 24 | $-0.15 | $-1.08 | ||
| Q2 24 | $-0.79 | $-1.46 | ||
| Q1 24 | $0.01 | $-1.48 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $6.1B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.9B | $4.6B |
| 总资产 | $8.5B | $14.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PRGORIVN
| Q4 25 | — | $6.1B | ||
| Q3 25 | $432.1M | $7.1B | ||
| Q2 25 | $454.2M | $7.5B | ||
| Q1 25 | $409.9M | $7.2B | ||
| Q4 24 | $558.8M | $7.7B | ||
| Q3 24 | $1.5B | $6.7B | ||
| Q2 24 | $542.8M | $7.9B | ||
| Q1 24 | $658.5M | $7.9B |
总债务PRGORIVN
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $5.5B | ||
| Q1 24 | — | $4.4B |
股东权益PRGORIVN
| Q4 25 | $2.9B | $4.6B | ||
| Q3 25 | $4.4B | $5.1B | ||
| Q2 25 | $4.5B | $6.1B | ||
| Q1 25 | $4.4B | $6.2B | ||
| Q4 24 | $4.3B | $6.6B | ||
| Q3 24 | $4.6B | $5.9B | ||
| Q2 24 | $4.5B | $6.8B | ||
| Q1 24 | $4.7B | $8.1B |
总资产PRGORIVN
| Q4 25 | $8.5B | $14.9B | ||
| Q3 25 | $10.1B | $15.2B | ||
| Q2 25 | $10.1B | $15.6B | ||
| Q1 25 | $9.8B | $15.5B | ||
| Q4 24 | $9.6B | $15.4B | ||
| Q3 24 | $11.2B | $14.3B | ||
| Q2 24 | $10.4B | $15.4B | ||
| Q1 24 | $10.6B | $15.7B |
负债/权益比PRGORIVN
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.81× | ||
| Q1 24 | — | 0.55× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $175.4M | $-681.0M |
| 自由现金流经营现金流 - 资本支出 | $148.6M | $-1.1B |
| 自由现金流率自由现金流/营收 | 13.4% | -89.0% |
| 资本支出强度资本支出/营收 | 2.4% | 36.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $145.1M | $-2.5B |
8季度趋势，按日历期对齐
经营现金流PRGORIVN
| Q4 25 | $175.4M | $-681.0M | ||
| Q3 25 | $51.7M | $26.0M | ||
| Q2 25 | $75.9M | $64.0M | ||
| Q1 25 | $-64.5M | $-188.0M | ||
| Q4 24 | $312.6M | $1.2B | ||
| Q3 24 | $42.2M | $-876.0M | ||
| Q2 24 | $9.5M | $-754.0M | ||
| Q1 24 | $-1.4M | $-1.3B |
自由现金流PRGORIVN
| Q4 25 | $148.6M | $-1.1B | ||
| Q3 25 | $29.8M | $-421.0M | ||
| Q2 25 | $56.7M | $-398.0M | ||
| Q1 25 | $-90.0M | $-526.0M | ||
| Q4 24 | $274.9M | $856.0M | ||
| Q3 24 | $15.1M | $-1.2B | ||
| Q2 24 | $-18.9M | $-1.0B | ||
| Q1 24 | $-26.5M | $-1.5B |
自由现金流率PRGORIVN
| Q4 25 | 13.4% | -89.0% | ||
| Q3 25 | 2.9% | -27.0% | ||
| Q2 25 | 5.4% | -30.5% | ||
| Q1 25 | -8.6% | -42.4% | ||
| Q4 24 | 24.2% | 49.4% | ||
| Q3 24 | 1.4% | -131.9% | ||
| Q2 24 | -1.8% | -89.6% | ||
| Q1 24 | -2.4% | -126.5% |
资本支出强度PRGORIVN
| Q4 25 | 2.4% | 36.0% | ||
| Q3 25 | 2.1% | 28.7% | ||
| Q2 25 | 1.8% | 35.5% | ||
| Q1 25 | 2.4% | 27.3% | ||
| Q4 24 | 3.3% | 18.9% | ||
| Q3 24 | 2.5% | 31.7% | ||
| Q2 24 | 2.7% | 24.4% | ||
| Q1 24 | 2.3% | 21.1% |
现金转化率PRGORIVN
| Q4 25 | — | — | ||
| Q3 25 | 6.89× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -0.70× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PRGO
| Consumer Self Care Americas | $697.0M | 63% |
| Digestive Health | $123.9M | 11% |
| Nutrition | $108.3M | 10% |
| Healthy Lifestyle | $94.8M | 9% |
| Pain And Sleep Aids | $87.1M | 8% |
RIVN
| Automotive Segment | $839.0M | 65% |
| Software And Services Segment | $447.0M | 35% |
| Regulatory Credits | $30.0M | 2% |
